Classic psychedelics, coupled with therapy have shown the potential to treat a vast range of indications. However, these molecules in their original form may not be the best option for every disease. For instance, treatment sessions can take up to 8 hours, adverse side effects (aka “bad trips”) are possible and the treatment can only be administered in a clinic. Simply put, what if there was a way to improve on classic psychedelics? In a recent study in Nature, a non-hallucinogenic derivative of ibogaine was shown to have therapeutic potential. |